FLUCLOXACILLIN KABI (Fresenius Kabi Australia Pty Ltd)
Product name
FLUCLOXACILLIN KABI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
141 (255 working days)
Active ingredients
flucloxacillin sodium monohydrate
Registration type
New generic medicine
Indication
FLUCLOXACILLIN KABI (powder for injection) is indicated for treatment of confirmed or suspected staphylococcal infections and other Gram-positive coccal infections including pneumonia, skin and skin structure and wound infections, infected burns and cellulitis.